Cellectar Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cellectar Biosciences (CLRB).

Price Target Range — 4 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$287Upside to Avg. PT+24640.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 15, 2026	Ladenburg Thalmann	Kevin DeGeeter	Assumes	Buy	$10
Mar 10, 2026	Maxim Group	Jason McCarthy	Upgrade	Hold→Buy	$10
May 14, 2025	Maxim Group	Jason McCarthy	Downgrade	Buy→Hold	—
Dec 11, 2024	Oppenheimer	Jeff Jones	Downgrade	Outperform→Perform	—
Nov 19, 2024	Oppenheimer	Jeff Jones	PT Cut	Outperform	$14→$12
Oct 11, 2024	Oppenheimer	Jeff Jones	Maintained	Outperform	$14
Mar 28, 2024	Roth MKM	Jonathan Aschoff	PT Raise	Buy	$20→$28
Mar 28, 2024	Oppenheimer	Jeff Jones	PT Raise	Outperform	$11→$12
Mar 4, 2024	Roth MKM	Jonathan Aschoff	Maintained	Buy	$20

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Ladenburg Thalmann Assumes Cellectar Biosciences at Buy, Announces Price Target of $10

Ladenburg Thalmann analyst Kevin DeGeeter assumes Cellectar Biosciences (NASDAQ:CLRB) with a Buy rating and announces Price Target of $10.

Benzinga Newsdesk

PRO
Maxim Group Upgrades Cellectar Biosciences to Buy, Announces $10 Price Target

Maxim Group analyst Jason McCarthy upgrades Cellectar Biosciences (NASDAQ:CLRB) from Hold to Buy and announces $10 price target.

Benzinga Newsdesk

PRO
Maxim Group Downgrades Cellectar Biosciences to Hold

Maxim Group analyst Jason McCarthy downgrades Cellectar Biosciences (NASDAQ:CLRB) from Buy to Hold.

Benzinga Newsdesk

PRO
Oppenheimer Downgrades Cellectar Biosciences to Perform

Oppenheimer analyst Jeff Jones downgrades Cellectar Biosciences (NASDAQ:CLRB) from Outperform to Perform.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Cellectar Biosciences, Lowers Price Target to $12

Oppenheimer analyst Jeff Jones maintains Cellectar Biosciences (NASDAQ:CLRB) with a Outperform and lowers the price target from $14 to $12.

Benzinga Newsdesk

PRO
Oppenheimer Reiterates Outperform on Cellectar Biosciences, Maintains $14 Price Target

Oppenheimer analyst Jeff Jones reiterates Cellectar Biosciences (NASDAQ:CLRB) with a Outperform and maintains $14 price target.

Benzinga Newsdesk

Cellectar Biosciences Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Cellectar Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Ladenburg Thalmann Assumes Cellectar Biosciences at Buy, Announces Price Target of $10

PRO
Maxim Group Upgrades Cellectar Biosciences to Buy, Announces $10 Price Target

PRO
Maxim Group Downgrades Cellectar Biosciences to Hold

PRO
Oppenheimer Downgrades Cellectar Biosciences to Perform

PRO
Oppenheimer Maintains Outperform on Cellectar Biosciences, Lowers Price Target to $12

PRO
Oppenheimer Reiterates Outperform on Cellectar Biosciences, Maintains $14 Price Target

People Also Watch

People Also Watch

Cellectar Biosciences Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Cellectar Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLadenburg Thalmann Assumes Cellectar Biosciences at Buy, Announces Price Target of $10

PROMaxim Group Upgrades Cellectar Biosciences to Buy, Announces $10 Price Target

PROMaxim Group Downgrades Cellectar Biosciences to Hold

PROOppenheimer Downgrades Cellectar Biosciences to Perform

PROOppenheimer Maintains Outperform on Cellectar Biosciences, Lowers Price Target to $12

PROOppenheimer Reiterates Outperform on Cellectar Biosciences, Maintains $14 Price Target

People Also Watch

People Also Watch

PRO
Ladenburg Thalmann Assumes Cellectar Biosciences at Buy, Announces Price Target of $10

PRO
Maxim Group Upgrades Cellectar Biosciences to Buy, Announces $10 Price Target

PRO
Maxim Group Downgrades Cellectar Biosciences to Hold

PRO
Oppenheimer Downgrades Cellectar Biosciences to Perform

PRO
Oppenheimer Maintains Outperform on Cellectar Biosciences, Lowers Price Target to $12

PRO
Oppenheimer Reiterates Outperform on Cellectar Biosciences, Maintains $14 Price Target